EUVIMEDEUVIMED entdecken
Open Access · CC BY 4.0

Agora: An open science platform that enables evidence‐based exploration of Alzheimer's Disease therapeutic targets

Jessica S Britton, Jesse C Wiley, Jaclyn Beck, Lawrence Yi, Beatriz Saldana, Brad Macdonald, Khai Do, Stockard Simon, Hallie Swan, Thomas Yu, Jay Hodgson, Anna Greenwood und 2 weitere

Alzheimer's & Dementia · 2025-12 · 21 (S1)

DOI: 10.1002/alz70855_098626 ↗

Kurz gefasst

Fachartikel in der Zeitschrift Alzheimer's & Dementia, online erschienen am 23.12.2025. Verfasst von Jessica S Britton und 13 weiteren Autor:innen. Die Arbeit wurde bisher 4-mal zitiert (Crossref). Der Volltext ist frei zugänglich (Open Access, CC BY 4.0).

AbstractBibliografische AngabenZitierenVerwandte Studien

Abstract (Originalsprache)

Background

Agora ( https://agora.adknowledgeportal.org ) is an openly available web application developed to enable a broad spectrum of Alzheimer's disease (AD) researchers access to the target‐based evidence generated within the translational research portfolio of the National Institute on Aging (NIA). Agora accelerates AD research and maximizes therapeutic discovery by sharing information using interactive tools, data visualizations, and summarized evidence.

Methods

Agora enables sharing information about potential AD therapeutic targets by surfacing data visualizations, aggregating summary evidence, and displaying results from targeted validation studies. Agora users can browse a list of over 950 potential therapeutic targets that have been nominated by the NIA's Accelerating Medicines Partnership in AD (AMP‐AD) consortium and Target Enablement to Accelerate Therapy Development for AD (TREAT‐AD) centers, and by the broader AD research community; see visualizations and summarized information based on harmonized genome‐wide analyses of high‐dimensional human transcriptomic, proteomic, and metabolomic data; use interactive tools designed to enable non‐bioinformaticians to evaluate and compare complex multi‐omic data; leverage results that objectively rank and organize targets based on their role in AD; investigate the experimental reagents and bioinformatics packages that are available to support further investigation of select targets; and access the underlying data that drives the results and visualizations presented in the application.

Results

Agora presents information and results about AD targets using approaches that make this information accessible to a broad spectrum of AD researchers. Recent updates to Agora include 1) new TREAT‐AD target nominations and 2) enhanced connections to external resources, including the introduction of a new drug development resource section and UniprotKB integration.

Conclusions

Advancing potential AD therapeutics through the drug development pipeline requires efforts from research groups and specialties spanning both academia and industry. Agora enables the AD research community to unite by enabling the development and sharing of target hypotheses to accelerate the investigation of promising new AD therapeutic targets, pathways and mechanisms.

Zitieren

APA

Britton, J. S., Wiley, J. C., Beck, J., Yi, L., Saldana, B., Macdonald, B., Do, K., Simon, S., Swan, H., Yu, T., Hodgson, J., Greenwood, A., Heath, L. M., & Leal, K. (2025). Agora: An open science platform that enables evidence‐based exploration of Alzheimer's Disease therapeutic targets. Alzheimer's & Dementia, 21(S1). https://doi.org/10.1002/alz70855_098626

Vancouver

Britton JS, Wiley JC, Beck J, Yi L, Saldana B, Macdonald B, et al. Agora: An open science platform that enables evidence‐based exploration of Alzheimer's Disease therapeutic targets. Alzheimer's & Dementia. 2025;21(S1). doi:10.1002/alz70855_098626

BibTeX
@article{Britton2025,
  author = {Britton, Jessica S and Wiley, Jesse C and Beck, Jaclyn and Yi, Lawrence and Saldana, Beatriz and Macdonald, Brad and Do, Khai and Simon, Stockard and Swan, Hallie and Yu, Thomas and Hodgson, Jay and Greenwood, Anna and Heath, Laura M and Leal, Karina},
  title = {Agora: An open science platform that enables evidence‐based exploration of Alzheimer's Disease therapeutic targets},
  journal = {Alzheimer's & Dementia},
  year = {2025},
  volume = {21},
  number = {S1},
  doi = {10.1002/alz70855_098626}
}
Kostenlos starten →